Tryp Therapeuatics (TRYPF) Coverage Report

between companies and sitting on their joint development teams. At QLT Mr. D’Orazio was responsible for managing their $500M/year commercial partnership with Novartis. Prior to working for QLT, Mr. D’Orazio was at Pfizer (Pharmacia U.S.A.) and managed a $250M/year portfolio that included human growth hormone where he was involved in the strategic planning for label expansion for the Prader-Willi syndrome indication. Mr. D’Orazio has an MBA from Vanderbilt University with an emphasis in both Finance and Marketing and a B.Sc. in chemistry from Loyola University of Chicago. Key members of the scientific advisory committee include: Robin Carhart-Harris, Ph.D., Chairman of the Scientific Advisory Board. Dr. Carhart- Harris is widely recognized renowned leader in neuroscience research. Recently, he became the Ralph Metzner Distinguished Professor of Neurology and Psychiatry at UCSF where he is also the Founding Director of the UCSF Neuroscape Psychedelics Division. Previously, he was the Head of the Centre for Psychedelic Research in the Department of Brain Sciences at Imperial College London where he has published numerous clinical trials studying the effects of psychedelics on the brain. While there, he has designed several functional brain imaging studies with psilocybin, LSD, MDMA and DMT. Dr. Carhart-Harris has published >100 papers in peer-reviewed scientific journals, five of which rank in the top ten for annual citation rate in the field of psychedelic science, including the top two overall. Dr. Carhart-Harris’ research has featured in major national and international media, including a popula r TEDx talk and has been a leading voice for psychedelic medicine at the World Economic Forum in Davos. His talks on psychedelic- assisted therapy play a significant role in the development of psychedelics as novel pharmaceuticals for the treatment of disorders currently underserved with existing therapies and is playing a crucial role in helping to shape Tryp's trial designs. Dr. Carhart- Harris obtained his PhD in Psychopharmacology from the University of Bristol after earning an MA in Psychoanalysis at Brunel University. He holds an honorary position at the University of Oxford. Joel Castellanos, M.D., Scientific Advisor. Dr. Joel Castellanos is a board-certified physical medicine and rehabilitation physician who is fellowship trained in pain medicine. Dr. Castellanos is a member of the "Psychedelics and Health Research Initiative" at UC San Diego "PHRI", a collaborative endeavor cutting across multiple divisions and departments of UC San Diego. Dr. Castellanos also serves as an associate professor in the Department of Anesthesiology at UC San Diego School of Medicine, instructing pain medicine fellows, as well as medical students, and residents in their pain rotations. Dr. Castellanos completed his fellowship in pain medicine at UC San Diego School of Medicine. He completed residency training in physical medicine and rehabilitation at University of Michigan Medical School, where he also completed a two-year program in healthcare administration. Dr. Castellanos earned his medical degree from University of Toledo College of Medicine in Ohio. Dr. Castellanos is board certified in physical medicine and rehabilitation and pain medicine. Dr. Castellanos is an active member of numerous medical organizations including the American Academy of Pain Medicine, the American Academy of Physical Medicine and Rehabilitation, the International Association for the Study of Pain, and the North American Neuromodulation Society. Daniel Clauw, M.D., Scientific Advisor. Dr. Clauw is a world-leading expert in fibromyalgia and other nociplastic pain indications, or pain that is believed to derive from a dysfunction of the central nervous system whose processing of pain signals has become distorted. He currently serves as Director of the Chronic Pain & Fatigue Research Center and Professor of Anesthesiology, Medicine, and Psychiatry at the University of Michigan Medical School. Dr. Clauw has participated in the development of all the currently approved treatments for fibromyalgia and brings decades of expertise in nociplastic pain to the SAB. Michael Higgins 212.409.2074 Tryp Therapeutics, Inc. (TRYPF) Page 36